Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan
Rhea-AI Filing Summary
Maze Therapeutics, Inc. officer Harold Bernstein (President, R&D & CMO) exercised stock options and sold shares on August 13, 2026 under a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,142 shares of common stock at an exercise price of $10.42 per share, reducing that option position and leaving 176,803 options outstanding from this award. The resulting 16,142 common shares were then sold at a weighted average price of $27.6063 per share, in multiple trades between $27.17 and $28.00. The options vest over four years, with 1/4 vested on October 3, 2023 and the remainder in equal monthly installments, conditioned on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 16,142 shares ($277K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Bernstein Harold
Role
President, R&D & CMO
Sold
16,142 shs ($446K)
Approx. gross sale proceeds
$446K
Approx. exercise cost
$168K
Approx. pre-tax spread
$277K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 16,142 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 16,142 | $10.42 | $168K |
| Sale | Common Stock F1, F2 | 16,142 | $27.6063 | $446K |
Holdings After Transaction:
Stock Option (Right to Buy) — 176,803 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $28.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Options exercised: 16,142 shares
Exercise price: $10.42 per share
Shares sold: 16,142 shares
+4 more
7 metrics
Options exercised
16,142 shares
Stock options for Maze Therapeutics common stock exercised on August 13, 2026
Exercise price
$10.42 per share
Exercise price of stock options converted into common stock
Shares sold
16,142 shares
Common stock sold on August 13, 2026 following option exercise
Weighted average sale price
$27.6063 per share
Weighted average price for shares sold, with trades from $27.17 to $28.00
Remaining options from award
176,803 shares
Stock options reported as beneficially owned after the transaction
Option expiration date
October 26, 2032
Expiration of the stock option from which shares were exercised
10b5-1 plan adoption date
September 29, 2025
Date Harold Bernstein adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), beneficially owned, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
beneficially owned financial
"the reporting person beneficially owned 176,803 shares underlying the option"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
vesting financial
"The option vested as to 1/4th of the total award and thereafter vested"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did MAZE executive Harold Bernstein report in this Form 4?
Harold Bernstein reported exercising 16,142 stock options at $10.42 per share and selling 16,142 common shares at a weighted average price of $27.6063 on August 13, 2026.
Was the MAZE Form 4 transaction by Harold Bernstein under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Harold Bernstein on September 29, 2025, indicating they followed a pre-arranged schedule.
How many Maze Therapeutics (MAZE) options does Harold Bernstein retain after this exercise?
After exercising, Harold Bernstein holds 176,803 stock options from the reported award. These options relate to Maze Therapeutics common stock and continue to be subject to their original terms, including the stated expiration date of October 26, 2032.
What are the key terms of Harold Bernstein’s MAZE stock option award?
The option has an exercise price of $10.42 per share, an expiration date of October 26, 2032, and vested 1/4 on October 3, 2023 with the remainder vesting in equal monthly installments contingent on continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
